PMC:4608092 / 24255-25426 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4608092","sourcedb":"PMC","sourceid":"4608092","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4608092","text":"Figure 4 Screening effects of angiogenic factors and antiangiogenic factors on RNF213 protein and mRNA expression in HUVECs. A through C, HUVECs were treated with various concentrations of angiogenic factors for 24 hours (A), or in the presence of 10 ng/mL of IFN-β (B) or IFN-γ (C) for the indicated times, and levels of RNF213 protein expression were examined by western blotting analysis using β-tubulin as a loading control. D through G, HUVECs were treated with various concentrations of IFN-β (D) or IFN-γ (F) for 24 hours or in the presence of 10 ng/mL of IFN-β (E) or IFN-γ (G) for the indicated times. RNA samples were analyzed by qPCR using PPIA as an internal control. Fold induction by IFN-β or IFN-γ was compared with activities of 0 ng/mL of IFN-β or IFN-γ. A column represents a mean of 3 independent experiments. Bars indicate SD. *P\u003c0.05, by Student t test compared with 0 ng/mL IFN-β or IFN-γ. HUVECs indicates human umbilical vein endothelial cells; IFN, interferon; IL, interleukin; PDGF-BB, platelet-derived growth factor; qPCR, quantitative polymerase chain reaction; TGF-β, transforming growth factor β; VEGF, vascular endothelial growth factor.\nF","tracks":[]}